The Technical Analyst
OptiNose Inc [OPTN]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
OptiNose Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.47% $0.954
America/New_York / 24 apr 2024 @ 12:27
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 107.41 mill |
| EPS: | -0.320 |
| P/E: | -2.98 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 112.65 mill |
| Avg Daily Volume: | 0.613 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.98 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -2.98 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.837 - 1.071 ( +/- 12.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Krick Anthony J | Sell | 2 345 | Common Stock |
| 2024-03-15 | Marino Michael F Iii | Buy | 3 816 | Common Stock |
| 2024-03-18 | Marino Michael F Iii | Sell | 15 059 | Common Stock |
| 2024-03-15 | Mahmoud Ramy A | Buy | 6 114 | Common Stock |
| 2024-03-18 | Mahmoud Ramy A | Sell | 19 198 | Common Stock |
| INSIDER POWER |
|---|
| -24.23 |
| Last 98 transactions |
| Buy: 6 923 187 | Sell: 11 541 596 |
Forecast:
14:06 - $0.953
Live Trading Signals (every 1 min)
Forecast
1: 12:36 - $0.953
Forecast 2: 13:26 - $0.954
Forecast 3: 14:06 - $0.953
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.954 (-1.47% ) |
| Volume | 0.158 mill |
| Avg. Vol. | 0.613 mill |
| % of Avg. Vol | 25.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OPTN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Latest Press Releases
2024-04-04 16:01:00 - Press Release
Optinose To Present At The Needham Virtual Healthcare Conference
Yardley, pa., april 04, 2024 (globe newswire) -- optinose (nasdaq:optn), a pharmaceutical company focused on patients treated by ear, nose and throat (ent) and allergy specialists, today announced that members of its management team will present a company overview and business update at the needham virtual healthcare conference on april 10, 2024 at 2:15 p.m. et.
2024-03-15 15:34:00 - Press Release
Xhance Approved By Fda As First And Only Medication Indicated For Treatment Of Adults With Chronic Rhinosinusitis Without Nasal Polyps
Reopen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps
2024-03-07 07:00:00 - Press Release
Optinose Reports Fourth Quarter And Full Year 2023 Financial Results and Recent Operational Highlights
Pdufa target action date is march 16, 2024, for the company's snda. if approved, the company is prepared for launch of xhance for treatment of patients diagnosed with chronic sinusitis
2024-02-29 16:40:00 - Press Release
Optinose Announces Reporting Date For Fourth Quarter 2023 Financial Results
Conference call and webcast to be held march 7, 2024, at 8:00 a.m. eastern time conference call and webcast to be held march 7, 2024, at 8:00 a.m. eastern time
2024-01-18 12:00:00 - Press Release
Optinose Announces The Publication Of Reopen Phase 3 Clinical Trial Program Evaluating Xhance In The Journal Of Allergy And Clinical Immunology: In Practice
Xhance significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled phase 3 clinical trials (reopen1 and reopen2)
Latest News
2024-04-04 16:01:00 - GlobeNewsWire
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
2024-03-07 09:16:16 - Zacks Investment Research
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
2024-02-29 16:40:00 - GlobeNewsWire
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
2023-10-24 13:32:37 - Zacks Investment Research
OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?
OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-09-22 09:01:00 - GlobeNewsWire
Optinose to Present at the 2023 Cantor Global Healthcare Conference
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.
2023-08-24 09:46:24 - Zacks Investment Research
5 Top-Ranked Stocks With Rising P/E for Solid Returns
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).
2023-08-10 10:01:06 - Zacks Investment Research
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
OptiNose (OPTN) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.23 per share a year ago.
2023-08-01 18:58:32 - Seeking Alpha
OptiNose: The Worst Has Been Avoided (Rating Upgrade)
On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023. OptiNose's preliminary net revenue for the second quarter of 2023 was $19.5 million, up 65.3% from the previous quarter and down 5.4% from the first quarter of 2022. On May 4, 2023, the company announced that the FDA had accepted a supplemental new drug application seeking approval for Xhance as a treatment for chronic sinusitis.
2023-06-02 13:00:00 - GlobeNewsWire
Optinose to Present at the Jefferies Healthcare Conference
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.
2023-05-11 17:57:10 - Seeking Alpha
OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript
OptiNose Inc. (NASDAQ:OPTN ) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call.